DSIP (Delta Sleep Inducing Peptide): The Sleep and Opioid Withdrawal Peptide Under FDA Review FDA update July 2026: An FDA advisory panel voted July 24 against recommending emideltide (DSIP) for the federal 503A compounding list the only one of seven peptides reviewed that was not recommended
The formulation described has not been reviewed by the FDA for safety or efficacy
Gastric irritation, liver stress, and systemic inflammation all respond to BPC-157 in animal models
This peptide is distinguished by its high affinity for binding to copper ions, a critical aspect since copper plays a pivotal role in various bodily functions
Flynn McGuire at the University of Utah, for example, said: The amount of hype to evidence is so skewed, its crazy, and that BPC-157 Should not be used by humans. At the same time, other physicians and researchers see things differently, and are prescribing BPC-157 for a wide variety of illnesses and injuries: ulcerative colitis, orthopedic injuries, and even mental health
The metabolic preservation data is also noteworthy